华润医药(03320)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03320 华润医药

未开盘 10-20 16:08:20

4.655

+0.050

+1.09%

最高4.755	最低4.630	成交量988.05万
今开4.685	昨收4.605	日振幅2.71%
总市值292.47亿	流通市值292.45亿	总股本62.83亿
成交额4,633万	换手率0.16%	流通股本62.83亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03320","market":"HK","secType":"STK","nameCN":"华润医药","latestPrice":4.655,"timestamp":1792483700006,"preClose":4.605,"halted":0,"volume":9880500,"delay":0,"changeRate":0.010857763300760003,"floatShares":6282510461,"shares":6283000000,"eps":0.643391,"marketStatus":"未开盘","change":0.05,"latestTime":"10-20 16:08:20","open":4.685,"high":4.755,"low":4.63,"amount":46326329,"amplitude":0.027144,"askPrice":4.655,"askSize":38500,"bidPrice":4.65,"bidSize":870000,"shortable":3,"etf":0,"ttmEps":0.763522,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792546200000},"marketStatusCode":0,"adr":0,"listingDate":1477584000000,"exchange":"SEHK","adjPreClose":4.605,"dividendRate":0.052663,"openAndCloseTimeList":[[1792459800000,1792468800000],[1792472400000,1792483200000]],"volumeRatio":0.9720282527132618,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03320","defaultTab":"news","newsList":[{"id":"1120303143","title":"华润医药（03320）完成9亿元第二期2026年公司债券公开发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1120303143","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120303143?lang=zh_cn&edition=full","pubTime":"2026-10-16 21:41","pubTimestamp":1792158077,"startTime":"0","endTime":"0","summary":"10月16日，华润医药（03320）公告称，其全资附属公司华润医药控股有限公司已在中国完成公开发行第二期2026年公司债券。本期债券发行规模为人民币9亿元，期限三年，票面年利率为1.48%。\\n\\n公司表示，第二期2026年公司债券的募集资金净额将用于生产性支出，包括偿还公司债务、补充营运资金、项目开发与营运支出、与科技创新相关的投资以及符合法律法规的其他用途。\\n\\n华润医药提醒股东及潜在投资者在买卖公司证券时保持审慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675970485","title":"华润医药(03320)附属完成发行9亿元公司债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2675970485","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675970485?lang=zh_cn&edition=full","pubTime":"2026-10-16 21:40","pubTimestamp":1792158021,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润医药(03320)发布公告，公司的全资附属公司华润医药控股有限公司(华润医药控股)已完成于中国公开发行第二期2026年公司债券。本金额人民币9亿元的第二期2026年公司债券已发行，期限三年，票面年利率为1.48%。发行第二期2026年公司债券所募集的所得款项净额将用于生产性支出，包括偿还公司债务、补充营运资金、项目开发与营运支出、与科技创新相关的投资以及符合适用法律法规的其他用途。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1508584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03320","BK1570","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675970125","title":"华润医药(03320.HK)附属完成发行9亿元公司债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2675970125","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675970125?lang=zh_cn&edition=full","pubTime":"2026-10-16 21:40","pubTimestamp":1792158021,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1570","03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119308434","title":"华润医药（03320.HK）旗下华润医药商业启动增资投标前程序","url":"https://stock-news.laohu8.com/highlight/detail?id=1119308434","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119308434?lang=zh_cn&edition=full","pubTime":"2026-10-16 20:45","pubTimestamp":1792154730,"startTime":"0","endTime":"0","summary":"2026年10月16日，华润医药集团有限公司公告称，其非全资附属公司华润医药商业集团有限公司已依据《企业国有资产交易监督管理办法》相关规定，通过北京产权交易所启动公开投标方式发行新股份的投标前程序。公告披露，华润医药商业已于2026年10月16日在北京产权交易所网站发布增资信息预披露申请书。公司强调，目前尚未就本次潜在发行签署任何具约束力协议，后续实施仍需完成北京产权交易所的正式公开投标程序。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675455167","title":"【券商聚焦】中信证券：市场风格趋于谨慎 中药高股息标的关注度持续上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2675455167","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675455167?lang=zh_cn&edition=full","pubTime":"2026-10-16 08:52","pubTimestamp":1792111979,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券表示，近期，市场风格趋于谨慎，中药高股息标的关注度持续上升。在此背景下，中药板块凭借\"低估值+高股息+成本端改善\"三重属性，成为具备高确定性的细分投资板块。该机构梳理两条投资主线：1）高股息率、业绩稳健标的。2）业绩边际向好、股息率具备一定吸引力的标的。风险因素：渠道库存积压的风险；业绩不及预期的风险；成本上涨的风险；集采不及预期的风险；重大支出后降低股息率的风险。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993818","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2580892789.USD","02273","LU1146622755.USD","BK0012","03613","BK0183","BK1197","LU2289578879.USD","QUSA","LU0405327148.USD","159207","06030","00570","BK1570","LU1064130708.USD","BK0188","LU1064131003.USD","LU1255011170.USD","LU1328615791.USD","02877","LU1794554557.SGD","BK1515","BK0276","LU1580142542.USD","02161","BK0196","LU1781817850.SGD","PRIZ","BK1564","LU1720050803.USD","CGVV","00874","LU2148510915.USD","PY","01643","KCE","BK1516","BK1521","03320","600030","FTDS","BK1191","LU0405327494.USD","LU1820825898.SGD","EASY","LU1997244956.HKD","ABEQ","BK1147","BK1219","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673044541","title":"中医药板块普涨 绿叶制药（02186）涨2.23%  机构指板块有望迎估值与业绩双重修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2673044541","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673044541?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:45","pubTimestamp":1791423956,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股中医药板块盘初普涨，截至发稿，中国中药 涨4.98%，吉林长龙药业涨3.23%，绿叶制药涨2.23%，白云山涨1.84%，神威药业涨1.42%，华润医药涨1.05%。随着基药目录红利的Q4落地、库存周期的边际改善以及成本红利的持续释放，板块有望迎来估值与业绩的双重修复。OTC板块核心变量是成本下行和渠道去库，Q4呼吸系统疾病发病率若季节性回升，感冒呼吸类OTC终端动销有望回暖；消费中药若消费环境边际回暖，品牌中药的收入端弹性较大。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993277","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08049","03320","02186","BK1521","00570","BK1515","BK1570","BK1583","02877","BK1606","BK1191","00874","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172305455","title":"华润医药2026年9月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1172305455","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172305455?lang=zh_cn&edition=full","pubTime":"2026-10-02 16:53","pubTimestamp":1790931226,"startTime":"0","endTime":"0","summary":"华润医药于2026年10月2日发布了截至2026年9月30日的股份变动月报表，披露公司当月股本及股份变动情况。根据报告，华润医药在本报告期内已发行股份总数与上月保持一致，维持在6,282,510,461股，暂未持有任何库藏股份。公司确认截至本月底继续符合在香港联交所上市所要求的最低公众持股量，股本保持稳定。公告由公司秘书温詠宜于2026年10月2日签署，华润医药方面表示，将继续遵守香港联交所《上市规则》及相关法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148967955","title":"华润医药2026年中期营收1344.58亿元，经调整净利润21.87亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1148967955","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148967955?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:12","pubTimestamp":1790208778,"startTime":"0","endTime":"0","summary":"截至2026年6月30日，华润医药实现营收约1344.58亿元，同比增长2.0%。经调整净利润约21.87亿元，同比增长5.3%。报告期内，整体毛利率从去年同期的16.3%略降至16.0%。经营活动产生的现金流约14.23亿元，较上年同期约15.31亿元略有下降。从成本结构来看，销售及分销开支约101.46亿元，相比去年同期的100.10亿元小幅增长；管理费用约33.44亿元，较上年同期略有上升。研发投入则达到13.6亿元，同比增加8.7%。制造业务报告期实现收入约244.45亿元，同比微降1.5%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润医药2026年中期营收1344.58亿元，经调整净利润21.87亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156483718","title":"华润医药子公司获准注册发行10亿元中期票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1156483718","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156483718?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:50","pubTimestamp":1788256255,"startTime":"0","endTime":"0","summary":"2026年9月1日，华润医药集团有限公司（03320，以下简称“华润医药”）公告称，其非全资附属公司昆药集团股份有限公司已收到中国银行间市场交易商协会出具的《接受注册通知书》（中市协注[2026]MTN682号）。\n\\n\\n通知书自发出日期起两年内有效。在此期间，昆药集团可分期发行总额不超过人民币10亿元的中期票据，发行地为中国银行间债券市场。\n\\n\\n华润医药表示，将在适当时候就拟议发行的具体安排发布进一步公告。公司同时提醒股东及潜在投资者，相关中期票据发行存在可能进行或不进行的情形，买卖公司证券时应保持审慎。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107134029","title":"华润医药：交易商协会公告发布","url":"https://stock-news.laohu8.com/highlight/detail?id=1107134029","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107134029?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:50","pubTimestamp":1788256215,"startTime":"0","endTime":"0","summary":"华润医药（03320.HK）方面传来最新动态——中国银行间市场交易商协会已就该公司相关事宜正式发布公告。此次公告的发出，无疑为市场参与者提供了新的关注焦点，也引发了投资者对该公司后续动向的密切关注。作为港股医药板块的重要成员，华润医药的每一步动作都备受资本市场瞩目。此番由全国性自律组织所披露的信息，其具体内容及潜在影响，有待各方进一步解读与分析。市场人士普遍认为，相关公告的发布或将对公司短期市场表现产生一定影响，但长期走势仍取决于其基本面与行业环境。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1570","03320","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168361489","title":"华润医药更新2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1168361489","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168361489?lang=zh_cn&edition=full","pubTime":"2026-09-01 16:51","pubTimestamp":1788252717,"startTime":"0","endTime":"0","summary":"华润医药（03320）于2026年9月1日公布了截至2026年8月31日的股份变动月报表。报告显示，公司全称为华润医药集团有限公司，在本期内未发生新增发行、回购或注销及库藏股等变动。\n根据公告披露，截至8月31日，华润医药普通股股份总数为6,282,510,461股，与上月底保持一致，库藏股份数目为0股，股本规模无变化。上述期间，公司股份期权计划项下未发行新股，期末可行使股份期权数量合计为628,450,646份，与上月底结存数相同。\n公告还指出，公司已符合香港联合交易所有限公司《上市规则》要求的最低公众持股量规范。截至2026年8月底，公司股本规模保持稳定，公告由公司秘书温詠宜签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182084083","title":"华润医药2026年上半年营收1115.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182084083","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182084083?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:26","pubTimestamp":1788172014,"startTime":"0","endTime":"0","summary":"本季度信息\n2026年1–6月，华润医药实现营业收入约1115.62亿元，同比上涨约2.87%。本期营业成本约1045.23亿元，较上年同期增加约2.99%。销售费用约27.81亿元，同比上升约6.81%。管理费用约11.75亿元，同比下降约5.09%。研发费用约0.14亿元，同比降幅约39.57%。财务费用约6.94亿元，较上年同期减少约7.47%。报告期内公司经营性现金流量净额为-21.02亿元，相较上年同期的-33.79亿元明显改善。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663074132","title":"华润医药(03320.HK)：华润医药商业上半年归母净利润9.3亿元 同比增加3.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663074132","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663074132?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:23","pubTimestamp":1788171837,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1570","BK1191","03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663324074","title":"华润医药(03320)：华润医药控股上半年归母净利润18.15亿元 同比增加3.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663324074","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663324074?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:11","pubTimestamp":1788171081,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润医药(03320)发布公告，公司的全资附属公司华润医药控股有限公司(华润医药控股)截至2026年6月30日止6个月取得营业收入人民币1353.45亿元(单位下同)，同比增加1.93%;归属于母公司所有者的净利润18.15亿元，同比增加3.13%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润医药(03320)：华润医药控股上半年归母净利润18.15亿元 同比增加3.13%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196210205","title":"华润医药2026年上半年营收1353.45亿元，经调整净利润51.76亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1196210205","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196210205?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:07","pubTimestamp":1788170835,"startTime":"0","endTime":"0","summary":"截至2026年6月30日，华润医药实现营收1353.45亿元，同比增长1.93%。经调整净利润为51.76亿元，同比下滑1.28%。同期经营利润为64.03亿元，经营利润率约4.73%，较上年同期小幅下降。报告期内，公司毛利率约16.71%，与上年同期的16.86%相比基本保持稳定。销售及管理费用合计133.83亿元，较上年同期小幅增长约1.79%。研发投入约11.13亿元，较上年同期的9.71亿元增长约14.66%，占营收比重为0.82%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662772258","title":"大行评级丨美银：下调华润医药目标价至5.7港元，重申“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662772258","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662772258?lang=zh_cn&edition=full","pubTime":"2026-08-27 11:15","pubTimestamp":1787800523,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["03320","BK1570","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662722687","title":"大行评级丨里昂：下调华润医药目标价至6.5港元，下调收入及净利润预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2662722687","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662722687?lang=zh_cn&edition=full","pubTime":"2026-08-27 11:07","pubTimestamp":1787800023,"startTime":"0","endTime":"0","summary":"里昂发表研报指，华润医药中期收入同比增长2%，净利润同比增长5.3%，大致符合市场预期。毛利率及经营利润率分别下跌0.3及0.4个百分点，主要受分销业务利润率受压的影响。基于中期业绩表现，里昂将华润医药2026至2028年收入预测分别下调3.4%、7%及9.7%，当中制药业务销售预测分别下调7.8%、14.3%及19.6%，净利润预测下调6.4%、10.8%及20.1%。该行将其目标价由7.2港元下调至6.5港元，维持“跑赢大市”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260827/32349383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["03320","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662279158","title":"美银证券：降华润医药(03320.HK)目标价至5.7港元 重申“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662279158","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662279158?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:07","pubTimestamp":1787735270,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03320","BK1191","BK1570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662796598","title":"里昂：维持华润医药(03320.HK)“跑赢大市”评级 目标价下调至6.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662796598","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662796598?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:15","pubTimestamp":1787732148,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1570","03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661856224","title":"华润医药(03320)发布中期业绩，股东应占溢利21.87亿元，同比增长5.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661856224","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661856224?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:39","pubTimestamp":1787560747,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润医药 发布截至2026年6月30日止六个月业绩，收益1344.576亿元，同比增长2%;公司权益股东应占溢利21.87亿元，同比增长5.3%;每股基本盈利0.35元，拟派中期股息每股0.087元。报告期内，集团制药业务实现分部收益244.447亿元，同比略降1.5%。制药业务毛利率为60.3%，较上年同期上升1.0个百分点。报告期内，集团医药零售业务取得收益63.372亿元，同比增长14.9%。其中，高值药品直送业务实现收益约48.3亿元，同比增长28.6%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润医药(03320)发布中期业绩，股东应占溢利21.87亿元，同比增长5.3%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1570","BK1191","03320"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.crpharm.com","stockEarnings":[{"period":"1week","weight":0.0344},{"period":"1month","weight":0.0701},{"period":"3month","weight":-0.0036},{"period":"6month","weight":-0.1596},{"period":"1year","weight":0.0333},{"period":"ytd","weight":0.1028}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":-0.0357},{"period":"3month","weight":-0.0412},{"period":"6month","weight":-0.079},{"period":"1year","weight":-0.077},{"period":"ytd","weight":-0.0688}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"华润医药集团有限公司是一家主要从事医药业务的投资控股公司。该公司通过四个分部运营业务。制药业务分部研发、制造及销售一系列药品及保健品。药品分销业务分部向医院、分销商及零售药店等药品制造商、器械制造商及配药商提供分销、仓储、物流及其他药品供应链增值解决方案及相关服务。药品零售业务分部经营零售药店。其他业务营运分部从事持有物业及其他业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.012707},{"month":2,"riseRate":0.7,"avgChangeRate":0.04534},{"month":3,"riseRate":0.5,"avgChangeRate":0.003155},{"month":4,"riseRate":0.7,"avgChangeRate":0.030364},{"month":5,"riseRate":0.5,"avgChangeRate":0.000616},{"month":6,"riseRate":0.3,"avgChangeRate":-0.002096},{"month":7,"riseRate":0.3,"avgChangeRate":-0.023787},{"month":8,"riseRate":0.4,"avgChangeRate":-0.009791},{"month":9,"riseRate":0.4,"avgChangeRate":-0.016796},{"month":10,"riseRate":0.3,"avgChangeRate":-0.019789},{"month":11,"riseRate":0.4,"avgChangeRate":0.010199},{"month":12,"riseRate":0.5,"avgChangeRate":-0.000983}],"exchange":"SEHK","name":"华润医药","nameEN":"CHINARES PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华润医药(03320)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华润医药(03320)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华润医药,03320,华润医药股票,华润医药股票老虎,华润医药股票老虎国际,华润医药行情,华润医药股票行情,华润医药股价,华润医药股市,华润医药股票价格,华润医药股票交易,华润医药股票购买,华润医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华润医药(03320)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华润医药(03320)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}